- GlaxoSmithKline's (GSK +1%) sales in China have been recovering since Q3, when revenue plummeted 61% following the emergence of accusations that the company bribed doctors.
- "The trend is definitely looking a bit more positive," says CFO Simon Dingemans. "We can see the future opportunities to rebuild the business as and when we get to the other side of the (bribery) inquiry."
- Meanwhile, a study from the Centers for Disease Control & Prevention has found that GSK's Rotarix vaccine for preventing severe diarrhea in infants could slightly increase the risk of bowel blockage. However, the problem isn't severe enough to warrant a change in recommendation for the vaccine's use.
- An FDA report on Merck's (MRK -1%) RotaTeq has come to a similar conclusion.
GSK's sales in China improving
Jan 15 2014, 09:54 ET